Nebenwirkungen · Lemtrada
LEMTRADA 12 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-130385 · Präparat HOS-096907
The table below is based on the pooled safety data on all LEMTRADA 12 mg-treated patients during all available follow up in clinical trials. Adverse reactions are listed by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) and Preferred Term (PT). Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions have been presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-27T09:05:00Z · SHA-256 4a59647f4edf42e6c99e73c878f7d28b70efecb02fbb6e5bd1c6d4a9e4e86b3d · Passage 3a590c6f306fc21bfddd619815ec6cbbeac35736e04e896147c6b375b3be219b · Zeichen 644–1285 im Abschnitt